Pharmaceutical product updates: SGLT2 chat, iron & prenatal vitamins
Sparse, conversational lunch with a contract sales rep — useful GP nuggets on dapagliflozin (Forxiga) vs empagliflozin (Jardiance) trial populations, Ferrograd iron tips, and a vitamin D / folate product note. Strong sponsored-content disclaimer below.
- Speaker
- Contract sales representative (name unclear on ASR; physiology background; taught medical-school physiology in the US; ~25 years on the Gold Coast). Previously on a GSK contract; new contract with AstraZeneca detailing Forxiga (dapagliflozin) plus older products (iron / prenatal vitamins discussed).
- Session context
- Otter id
_2BAIC7mGS8FvcXuIvH8KdWn_fU· title Pharmaceutical Product Updates · ~22.1 min (1323 s). Clinic lunch conversation — not a formal lecture. ASR is noisy; numbers below are as stated in the transcript, not independently verified here.
This was a product lunch with a contract sales organisation representative currently contracted to AstraZeneca (Forxiga). Content is promotional and incomplete. The rep himself noted he was “only supposed to” stay within certain messaging (e.g. type 2 diabetes / glycaemic framing) but discussed broader mortality/CKD/HF comparisons. Do not change prescribing from this page alone. Cross-check PI, PBS criteria, and peer-reviewed evidence (DAPA-CKD, EMPA-REG / EMPEROR, DECLARE, etc.).
What a GP can still take away
- SGLT2 inhibitors have moved far beyond “diabetes pills” — endpoint data (HF, CKD, CV death / all-cause mortality depending on trial) is why GPs care.
- Head-to-head marketing claims are common; trial populations differ — compare like with like, not slide decks alone.
- Both Forxiga and Jardiance were described as similar on PBS suitability in the talk; both placebo-controlled landmark programs.
- Iron: modified-release / vitamin C combos and alternate-day dosing come up often in real clinics when daily iron fails GI tolerance.
- Prenatal products: check folate dose (e.g. 800 micrograms pregnancy vs step-down in breastfeeding in the product discussed) and vitamin D microgram strength against Australian standards.
SGLT2 conversation (Forxiga vs Jardiance)
The rep described a physiology lens on SGLT2s after years detailing ACE inhibitors / ARBs and cardio-metabolic drugs (Solvay/Abbott era). Key framing from the conversation:
- Endpoint data with or without diabetes impressed him — all-cause mortality signal discussed for the class / specific programs.
- DAPA program (dapagliflozin / Forxiga): larger trial numbers emphasised; DAPA-CKD singled out; “74 patients… saved” in 2.4-year follow-up quoted for DAPA-CKD (verify in the paper — promotional recall).
- Empagliflozin (Jardiance): heart-failure / higher-risk event populations said to sit closer to the mortality data in some comparisons the rep ran (including asking an AI tool the day before).
- Claimed absolute risk reduction / NNT figures in talk: ARR ~5.1 in one framing; individual trials “around three”; NNT “14” — treat as unverified promotional numbers.
- Mention that ~38% in a referenced trial had diabetes — useful reminder that many SGLT2 outcome patients are not purely “diabetic clinic” patients.
- Mechanistic chat in the room: natriuresis / volume, BP, possible epicardial fat effects (speculative in conversation), multi-system benefit narrative.
He said AstraZeneca training expected him to stay closer to type 2 diabetes / glycaemic messaging, and that he was “not supposed to go into that much detail” on some mortality comparisons — then discussed them anyway. Treat that as a flag for promotional over-reach.
Tolerability notes from the room
Clinic staff/doctors in the room reported SGLT2s as generally well tolerated after ~13 years of availability; UTI side-effect “hasn’t occurred” in their personal experience (anecdote — trials still list genital/UTI signals). Volume / BP effects acknowledged; diuretic-like sodium/fluid loss discussed qualitatively.
Iron — Ferrograd / Ferrograd C
Conversation shifted to familiar iron brands the rep had detailed since ~2003:
- Modified-release iron discussed as better tolerated for some.
- Nurse anecdote: diarrhoea with Ferrograd C after not responding to multiple irons; switched to Ferrograd (without C?) and tolerated; now twice-weekly maintenance.
- Room consensus: haematologists often use alternate-day dosing when daily iron is not tolerated — still effective for many; humans are not standard doses.
- Vitamin C co-formulation may help some absorbers; not mandatory for everyone.
Vitamin D & folate product notes
- One product highlighted as “new” mainly for 1000 micrograms vitamin D (confirm units / Australian labelling — transcript said micrograms).
- Folate: 800 micrograms in the Elevate-style pregnancy product discussed; steps down to 500 micrograms in the breastfeeding formulation — said to “make sense.”
- Brief mention of a combination (steroid? / saturation language unclear on ASR — possibly a topical or other detailer product) claimed better together than alone; too unclear to teach from — omitted as actionable advice.
- Calcitriol pronunciation banter — no dosing advice extractable.
Clinic checklist
- For SGLT2 choice: map indication (T2D, HF, CKD, CV risk) → PBS → comorbidity → patient preference; do not rely on lunch NNT claims.
- Re-read primary outcome papers when a rep asserts “unmatched mortality.”
- Iron intolerance: consider alternate-day oral before abandoning oral therapy; trial MR ± vitamin C formulations.
- Prenatals: check folate and vitamin D strengths against pregnancy stage and Australian guidance.
- Log sponsored lunches as promotional CPD context, not unbiased education.